Table 1.
Baseline characteristics of studied HCV/HIV-coinfected patients.
| Characteristics | Patients (N = 793) |
| Age at enrollment (years) | 38.0 (33.0–44.0) |
| Male | 640 (81.7) |
| BMI (kg/m2) | 19.9 (18.4–21.9) |
| HIV transmission | 793 |
| IDU | 494 (62.3) |
| Sexual | 245 (30.9) |
| Other | 54 (6.8) |
| CD4 count (cells/μL) | 119.0 (32.0–236.0) |
| CD4 count categories | 781 |
| <200 (cells/μL) | 523 (67.0) |
| 200–350 (cells/μL) | 190 (24.3) |
| 351–500 (cells/μL) | 49 (6.3) |
| >500 (cells/μL) | 19 (2.4) |
| CD4/CD8 ratio | 0.158 (0.058–0.289) |
| HIV RNA (log10 copies/mL)∗ | 4.7 (3.9–5.1) |
| Initial antiretroviral regimen | 793 |
| NRTIs + NNRTIs | 641 (80.8) |
| NRTIs + PIs | 93 (11.7) |
| Other regimens/unknown | 59 (7.4) |
| Liver cirrhosis | 188 (23.7) |
| Platelet (×109/L) | 163.0 (114.0–207.0) |
| Hemoglobin (g/L) | 123.0 (105.0–139.0) |
| ALT (U/L) | 37.0 (26.0–56.8) |
| Albumin (g/L) | 38.0 (31.0–42.1) |
| Total bilirubin (μmol/L) | 9.1 (6.8–12.5) |
| HBsAg positive | 130/770 (16.9) |
| HCV RNA (log10 IU/mL) | 6.0 (3.7–6.8) |
| Undetectable HCV RNA | 141 (17.8) |
| HCV genotype | 244 |
| 1 | 40 (16.4) |
| 2 | 6 (2.5) |
| 3 | 68 (27.9) |
| 6 | 130 (53.3) |
Data are presented as n, n/N (%), n (%) or median (interquartile range). ∗Data were available for 157 patients.
ALT: Alanine aminotransferase; BMI: Body mass index; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; IDU: Intravenous drug-using; NNRTIs: Non-nucleoside reverse transcriptase inhibitors; NRTIs: Nucleoside reverse transcriptase inhibitors; PIs: Protease inhibitors.